{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:13:26Z","timestamp":1768216406266,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>Specific treatment of pulmonary hypertension (PH) can improve right heart function and exercise endurance, but many adverse reactions caused by specific drugs should not be ignored. Existing basic and clinical studies suggest that sodium-glucose cotransporter 2 inhibitors (SGLT2-i) may be useful in patients with PH and improve their prognosis to some extent. Exploring the efficacy and safety of specific treatments combined with dapagliflozin (DAPA) in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), and to provide a clinical basis for new therapeutic possibilities for pulmonary vascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is a prospective, exploratory study that includes patients who attended the First Hospital of Jilin University from 2022 to 2024, divided into DAPA group and historical control group. The clinical data of the patients before and after treatment were compared. The primary endpoint event is defined as the improvement in 6\u2005min walk distance (6MWD). Adverse events were defined as hemoglobin decreased, liver and kidney damage, urinary tract infection, severe hypoglycemia and hypotension, and ionic disturbances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      73 patients were finally included in this study, including 28 in the DAPA group and 45 in the control group, with an average age of 44.99\u2009\u00b1\u200914.14 years. After 3 months of treatment, a comparison was made between the two groups, there was no statistically significant difference in 6MWD (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05). Compared with before treatment, the hemoglobin (146.80\u2009\u00b1\u200924.94 vs. 139.78\u2009\u00b1\u200923.57,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05) in the control group decreased significantly after treatment, while the hemoglobin in the DAPA group (155.25\u2009\u00b1\u200931.30 vs. 154.04\u2009\u00b1\u200931.93,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05) showed no significant change.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Studies have shown that the application of specific drugs can significantly improve the right heart function and activity endurance of patients with PAH and CTEPH. When combined with DAPA treatment, no significant additional benefits have been observed. However, DAPA treatment can alleviate the decrease in hemoglobin caused by the disease or drug reasons in patients with PH, and reduce the side effects caused by specific drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1684394","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:13:44Z","timestamp":1768205624000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of specific treatment combined with SGLT2-i in pulmonary hypertension"],"prefix":"10.3389","volume":"12","author":[{"given":"Chunyan","family":"Rong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00486-7","article-title":"Pulmonary hypertension","volume":"10","author":"Mocumbi","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC","volume":"44","author":"Mcdonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E876","DOI":"10.1161\/cir.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101491","DOI":"10.4330\/wjc.v17.i1.101491","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling","volume":"17","author":"Zhang","year":"2025","journal-title":"World J Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010042","article-title":"Impact of SGLT2 inhibitor therapy on right ventricular function in patients with heart failure and reduced ejection fraction","volume":"12","author":"Mustapic","year":"2023","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12351","article-title":"Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: a multicenter retrospective study","volume":"14","author":"Zhao","year":"2024","journal-title":"Pulm Circ"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-01939-7","article-title":"Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension","volume":"22","author":"Tang","year":"2022","journal-title":"BMC Pulm Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1080\/21655979.2021.2017652","article-title":"Protective effects of dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline","volume":"13","author":"Qin","year":"2022","journal-title":"Bioengineered"},{"key":"B10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ehf2.14169","article-title":"Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease","volume":"10","author":"Dai","year":"2023","journal-title":"Esc Heart Failure"},{"key":"B11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","article-title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","volume":"524","author":"Chowdhury","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jjcc.2022.10.003","article-title":"Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice","volume":"81","author":"Joki","year":"2023","journal-title":"J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1253\/circj.CJ-20-0341","article-title":"Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients - A randomized controlled trial","volume":"84","author":"Kayano","year":"2020","journal-title":"Circ J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1177\/02676591221127924","article-title":"A study of the efficacy of sacubitril\/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease","volume":"38","author":"Ge","year":"2022","journal-title":"Perfusion"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension","volume":"327","author":"Ruopp N","year":"2022","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(24)00027-4","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1) results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study","volume":"12","author":"Ghofrani","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension","volume":"52","author":"Ja\u00efs","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203396","article-title":"The crucial impact of iron deficiency definition for the course of precapillary pulmonary hypertension","volume":"13","author":"Sonnweber","year":"2018","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S2213-2600(17)30161-3","article-title":"Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study","volume":"5","author":"Rhodes","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4119891","DOI":"10.1161\/circ.150.suppl_1.4119891","article-title":"Risk factors of Anemia in pulmonary arterial hypertension patients with endothelin receptor antagonists administration and related treatment","volume":"150","author":"Xin","year":"2024","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5339\/gcsp.2014.21","article-title":"Riociguat: PATENT-1 study","volume":"2014","author":"Said","year":"2014","journal-title":"Glob Cardiol Sci Pract"},{"key":"B25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21037\/cdt.2019.03.02","article-title":"A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension","volume":"9","author":"Zhang","year":"2019","journal-title":"Cardiovasc Diagn Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e20997","DOI":"10.7759\/cureus.20997","article-title":"An unlikely trio: profound Anemia, elevated lactate, and riociguat","volume":"14","author":"Farmer","year":"2022","journal-title":"Cureus"},{"key":"B28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.nefro.2023.11.001","article-title":"Effect of SGLT2 inhibitors on anemia and their possible clinical implications","volume":"44","author":"Cases","year":"2024","journal-title":"Nefrologia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: data from the empire HF trial","volume":"25","author":"Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.2337\/dc22-0866","article-title":"Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS","volume":"45","author":"Koshino","year":"2022","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 Inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1684394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:13:45Z","timestamp":1768205625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1684394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2025.1684394"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1684394","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1684394"}}